⌘K
t
On 26 September 2025, Mark Nurse, a person closely associated with Thruvision Group plc Non-Executive Director Katrina Nurse, sold 10,000 ordinary shares in the company at 1.23 pence per share. Following this transaction, the beneficial shareholding of Katrina Nurse and her PCAs totals 258,000 ordinary shares, representing 0.06% of Thruvision Group plc's total issued share capital and voting rights.
| Date | 29 Sept 2025 |
| Time | 11:26:58 |
| Category | Director/PDMR dealings |
| ID | 2230B |
Thruvision Group plc
("Thruvision" or the "Company")
Director Share Dealing
Thruvision (AIM: THRU, "Thruvision" or the "Group"), the leading international provider of walk- through security technology, announces that on 26 September 2025 Mark Nurse, the husband and accordingly a person closely associated ("PCA") with Katrina Nurse, sold 10,000 ordinary shares in the Company at a price of 1.23 pence.
Following this transaction, the beneficial shareholding in the Company of Katrina Nurse and her PCAs is 258,000 ordinary shares, representing 0.06% of the Company's total issued share capital and total voting rights.
The notification below, made in accordance with the requirements of the Market Abuse Regulation, provides further detail:
|
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
(a) |
Name |
Mark Nurse, husband of Katrina Nurse |
|
|
2. |
Reason for the notification |
||
|
(a) |
Position/status |
Person closely associated with Katrina Nurse, a Non-Executive Director |
|
|
(b) |
Initial notification/ Amendment |
Initial notification |
|
|
3. |
Details of the issuer |
||
|
(a) |
Name |
Thruvision Group plc |
|
|
(b) |
LEI |
213800IZG9GM6G2TZE04 |
|
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
(a) |
Description of the Financial Instrument |
Ordinary shares of £0.01 each |
|
|
(b) |
Identification code of the Financial Instrument |
GB00B627R876 |
|
|
(c) |
Nature of the transaction |
Sale of shares
|
|
|
(d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
|
1.23 pence |
10,000 |
|
|
|
|
|
|
(e) |
Aggregated information - Aggregated volume - Price |
N/A |
|
|
(f) |
Date of the transaction |
26 September 2025 |
|
|
(g) |
Place of the transaction |
London Stock Exchange |
|
For further information please contact:
|
Thruvision Group plc Tom Black, Executive Chairman Victoria Balchin, Chief Executive Officer and Chief Financial Officer |
+44 (0)1235 425 400 |
|
|
|
|
Allenby (Nominated Adviser & Broker) James Reeve / Piers Shimwell (Corporate Finance) Jos Pinnington / Amrit Nahal (Sales) |
+44 (0)20 3328 5656 |
|
|
|
About Thruvision (www.thruvision.com)
Thruvision is a leading developer, manufacturer and supplier of advanced AI-based walk- through security technology internationally. Its technology is deployed in more than 30 countries around the world by government and commercial organisations in a wide range of security situations, where large numbers of people need to be screened quickly, safely and efficiently. Thruvision's patented technology is uniquely capable of detecting concealed objects in real time using advanced AI-based detection algorithms. The Group's offices are near Oxford and Washington DC.